A short half-life of the administered factor XIII (FXIII) concentrates after the first replacement therapy in a newborn with severe congenital FXIII deficiency

Thrombosis and Haemostasis

Volumn 107, Issue 3, 2012, Pages 592-594

  Fujii, Noriko ^a   Souri, Masayoshi ^b   Ichinose, Akitada ^b  

^a Fukuchiyama City Hospital   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE;

ANEMIA; BLEEDING; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRAIN HEMORRHAGE; DISEASE COURSE; DRUG DOSE INCREASE; GENE MUTATION; GENE SEQUENCE; HALF LIFE TIME; HEMOSTASIS; HUMAN; LABORATORY TEST; LETTER; NEWBORN; PRIORITY JOURNAL; SUBSTITUTION THERAPY;

DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FACTOR XIII; FACTOR XIII DEFICIENCY; HALF-LIFE; HEMORRHAGE; HEMOSTASIS; HUMANS; INFANT, NEWBORN; JAPAN; MALE; RECURRENCE; TIME FACTORS; UMBILICAL CORD;

EID: 84857721183     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-09-0625     Document Type: Letter

References (21)

1. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001; 86: 57-65.
2. Karimi M, Bereczky Z, Cohan N, et al. Factor XIII Deficiency. Semin Thromb Hemost 2009; 35: 426-438.
3. Kohler HP, Ichinose A, Seitz R, et al., on behalf of the Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-1406.
4. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-484.
5. Biswas A, Ivaskevicius V, Seitz R, et al. An update of the mutation profile of Factor 13 A and B genes. Blood Rev 2011; 25: 193-204.
6. Lusher J, Pipe SW, Alexander S, et al. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-321.
7. Dreyfus M, Arnuti B, Beurrier P, et al. Safety and efficacy of Fibrogammin Poofor the treatment of patients with severe FXIII deficiency. J Thromb Haemost 2003; 1 (Suppl 1): P0299.
8. Nugent DJ. Prophylaxis in rare coagulation disorders--factor XIII deficiency. Thromb Res 2006; 118 (Suppl 1): S23-28.
9. Schroeder V, Durrer D, Meili E, et al. Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterisation in 2005. Swiss Med Wkly 2007; 137: 272-278.
10. Ichinose A. Hemorrhagic Acquired Factor XIII (13) Deficiency and Acquired Hemorrhaphilia 13 Revisited. Semin Thromb Hemost 2011; 37: 382-388.
11. Shirahata A, Nakamura T, Shiiki M. Pathophysiology of Coagulation in the Newborn Infant. Rinsho Ketsueki 1987; 28: 1065-1074.
12. Shirahata A, Nakamura T, Shimono M, et al. Blood coagulation findings and the efficacy of factor XIII concentrate in premature infants with intracranial hemorrhages. Thromb Res 1990; 57: 755-763.
13. Pinacho A, Páramo JA, Ezcurdia M, et al. Evaluation of the fibrinolytic system in full-term neonates. Int J Clin Lab Res 1995; 25: 149-152.
14. Anwar R, Minford A, Gallivan L, et al. Delayed umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109: E32.
15. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 5: 372-375.
16. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14: 1190-1200.
17. Fear JD, Miloszewski KJ, Losowsky MS. The half life of factor XIII in the management of inherited deficiency. Thromb Haemost 1983; 49: 102-105.
18. Sugimura T, Tanaka A, Sato T, et al. Study on BI71.023 (XIII factor concentrated pharmaceutical of Pasteur method processing blood plasma derivation) of in vivo recovery percentage and half time in congenital XIII factor deficiency patient. J New Rem Clin 1993; 42: 1368-1375.
19. Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-625.
20. Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
21. Theusinger OM, Baulig W, Asmis LM, et al. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost 2010; 104: 385-391.